Linked Life Data

12499186

Source:http://linkedlifedata.com/resource/pubmed/id/12499186

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2002-12-24
pubmed:abstractText
Pneumococcal resistance to antimicrobials presents problems to physicians for empirical treatment of acute otitis media (AOM). Three hundred thirty-three isolates of Streptococcus pneumoniae selected for nonsusceptibility to penicillin (MIC >0.1 microg/ml) from the middle ear (n = 325) or mastoid (n = 8) of children seen between 1994 and 2000 at four children's hospitals in the United States were tested by broth microdilution for susceptibility to nine antibiotics. Using NCCLS 2002 breakpoints, resistance to the following drugs was as indicated: amoxicillin, 1%; azithromycin, 71%; cefprozil, 71%; ceftriaxone, 2%; cefdinir, 98%; erythromycin, 70%; levofloxacin, 0%; and trimethoprim-sulfamethoxazole, 93%. Of the penicillin- and erythromycin-nonsusceptible isolates, 97% were inhibited by cethromycin (ABT-773) and 83% were inhibited by telithromycin at a concentration of <or=0.125 microg/ml. Macrolide resistance among penicillin-nonsusceptible pneumococci increased from 44 to 80% in the 6 years of the study from which the isolates were selected; however, the proportion of isolates with M or MLS(B) phenotypes remained constant over the time period (53 and 18%, respectively). Prior treatment with a macrolide or clindamycin alone or in combination with a beta-lactam resulted in 94 or 85% of isolates causing infections being macrolide and or clindamycin resistant. No prior individual macrolide (azithromycin, erythromycin, or clarithromycin) resulted in more macrolide resistance or in a more prevalent resistance phenotype. The ketolides appear to be active antimicrobials against penicillin- and macrolide-resistant pneumococci.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/12499186-10207772, http://linkedlifedata.com/resource/pubmed/commentcorrection/12499186-10790089, http://linkedlifedata.com/resource/pubmed/commentcorrection/12499186-10858350, http://linkedlifedata.com/resource/pubmed/commentcorrection/12499186-11023465, http://linkedlifedata.com/resource/pubmed/commentcorrection/12499186-11158772, http://linkedlifedata.com/resource/pubmed/commentcorrection/12499186-11176564, http://linkedlifedata.com/resource/pubmed/commentcorrection/12499186-11353617, http://linkedlifedata.com/resource/pubmed/commentcorrection/12499186-11408241, http://linkedlifedata.com/resource/pubmed/commentcorrection/12499186-11462184, http://linkedlifedata.com/resource/pubmed/commentcorrection/12499186-9738174, http://linkedlifedata.com/resource/pubmed/commentcorrection/12499186-9798031, http://linkedlifedata.com/resource/pubmed/commentcorrection/12499186-9925532
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
47
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
166-9
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillin or macrolides.
pubmed:affiliation
Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA. emason@bcm.tmc.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't